AR043252A1 - Formulaciones de glucocorticoesteroides para tratar angiogenia ocular patologica - Google Patents
Formulaciones de glucocorticoesteroides para tratar angiogenia ocular patologicaInfo
- Publication number
- AR043252A1 AR043252A1 ARP040100545A ARP040100545A AR043252A1 AR 043252 A1 AR043252 A1 AR 043252A1 AR P040100545 A ARP040100545 A AR P040100545A AR P040100545 A ARP040100545 A AR P040100545A AR 043252 A1 AR043252 A1 AR 043252A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulations
- glucocorticoesteroids
- angiogenia
- treat pathological
- pathological eye
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001575 pathological effect Effects 0.000 title abstract 2
- YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 abstract 1
- 206010030113 Oedema Diseases 0.000 abstract 1
- 229960001232 anecortave Drugs 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44894403P | 2003-02-20 | 2003-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR043252A1 true AR043252A1 (es) | 2005-07-20 |
Family
ID=32908675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100545A AR043252A1 (es) | 2003-02-20 | 2004-02-20 | Formulaciones de glucocorticoesteroides para tratar angiogenia ocular patologica |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20060074061A1 (https=) |
| EP (1) | EP1594511A2 (https=) |
| JP (2) | JP2006518383A (https=) |
| KR (1) | KR20050102653A (https=) |
| CN (1) | CN100431544C (https=) |
| AR (1) | AR043252A1 (https=) |
| AU (1) | AU2004212900A1 (https=) |
| BR (1) | BRPI0407742A (https=) |
| CA (1) | CA2516790A1 (https=) |
| MX (1) | MXPA05008396A (https=) |
| PL (1) | PL378209A1 (https=) |
| RU (1) | RU2005129278A (https=) |
| TW (1) | TW200507858A (https=) |
| UY (1) | UY28203A1 (https=) |
| WO (1) | WO2004073608A2 (https=) |
| ZA (1) | ZA200505990B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2539023A1 (en) * | 2003-09-23 | 2005-04-14 | Alcon Inc. | Triamcinolone acetonide and anecortave acetate formulations for injection |
| US7257366B2 (en) * | 2003-11-26 | 2007-08-14 | Osmosis Llc | System and method for teaching a new language |
| KR20080059175A (ko) * | 2005-09-07 | 2008-06-26 | 사우스웨스트 리서치 인스티튜트 | 방출속도가 향상된 생분해성 미립자 약제학적 제제 |
| US9693967B2 (en) | 2005-09-07 | 2017-07-04 | Southwest Research Institute | Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates |
| CN101346473A (zh) * | 2005-12-22 | 2009-01-14 | 爱尔康研究有限公司 | 用于在具有补体因子h的风险变体的患者中预防和治疗年龄相关性黄斑变性的c3-转化酶抑制剂 |
| US20070173538A1 (en) * | 2005-12-23 | 2007-07-26 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| GB0625844D0 (en) * | 2006-12-22 | 2007-02-07 | Daniolabs Ltd | The treatment of macular degeneration |
| JP2010534201A (ja) * | 2007-07-20 | 2010-11-04 | アルコン，インコーポレイテッド | 受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の目への送達のための医薬製剤 |
| EP2977084B1 (en) * | 2010-05-10 | 2017-07-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of fluid accumulation in and/ or under the retina |
| US20170106047A1 (en) * | 2014-06-12 | 2017-04-20 | The Research Foundation For The State University Of New York | Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4975537A (en) * | 1985-10-23 | 1990-12-04 | The Upjohn Company | Δ9(11) -angiostatic steroids |
| US4686214A (en) * | 1985-10-30 | 1987-08-11 | Alcon Laboratories, Inc. | Anti-inflammatory compounds for ophthalmic use |
| US4771042A (en) * | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
| US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US5371078A (en) * | 1988-10-31 | 1994-12-06 | Alcon Laboratories, Inc. | Angiostatic steroids and methods and compositions for controlling ocular hypertension |
| US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
| US5556848A (en) * | 1993-12-27 | 1996-09-17 | Senju Pharmaceutical Co., Ltd. | Ophthalmic suspension containing diflupredonate |
| US5646136A (en) * | 1994-01-04 | 1997-07-08 | Duke University | Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids |
| US5516522A (en) * | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| US5736152A (en) * | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6011023A (en) * | 1997-08-27 | 2000-01-04 | Alcon Laboratories, Inc. | Angiostatic steroids |
| ATE283013T1 (de) * | 1999-10-21 | 2004-12-15 | Alcon Inc | Medikamentenzuführvorrichtung |
| US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| PT1221918E (pt) * | 1999-10-21 | 2005-06-30 | Alcon Inc | Administracao de drogas sub-tenon |
| US20040127472A1 (en) * | 2002-08-05 | 2004-07-01 | Jerdan Janice A. | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
-
2004
- 2004-02-05 MX MXPA05008396A patent/MXPA05008396A/es unknown
- 2004-02-05 CA CA002516790A patent/CA2516790A1/en not_active Abandoned
- 2004-02-05 CN CNB2004800043514A patent/CN100431544C/zh not_active Expired - Fee Related
- 2004-02-05 BR BRPI0407742-3A patent/BRPI0407742A/pt not_active IP Right Cessation
- 2004-02-05 US US10/545,053 patent/US20060074061A1/en not_active Abandoned
- 2004-02-05 US US10/772,963 patent/US20040167109A1/en not_active Abandoned
- 2004-02-05 PL PL378209A patent/PL378209A1/pl unknown
- 2004-02-05 JP JP2006503391A patent/JP2006518383A/ja active Pending
- 2004-02-05 ZA ZA200505990A patent/ZA200505990B/xx unknown
- 2004-02-05 KR KR1020057015189A patent/KR20050102653A/ko not_active Withdrawn
- 2004-02-05 EP EP04708663A patent/EP1594511A2/en not_active Withdrawn
- 2004-02-05 WO PCT/US2004/003515 patent/WO2004073608A2/en not_active Ceased
- 2004-02-05 AU AU2004212900A patent/AU2004212900A1/en not_active Abandoned
- 2004-02-05 RU RU2005129278/14A patent/RU2005129278A/ru not_active Application Discontinuation
- 2004-02-19 UY UY28203A patent/UY28203A1/es not_active Application Discontinuation
- 2004-02-19 TW TW093104085A patent/TW200507858A/zh unknown
- 2004-02-20 AR ARP040100545A patent/AR043252A1/es not_active Application Discontinuation
-
2006
- 2006-12-01 JP JP2006326249A patent/JP2007056041A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2005129278A (ru) | 2006-01-27 |
| WO2004073608A3 (en) | 2005-03-24 |
| JP2007056041A (ja) | 2007-03-08 |
| EP1594511A2 (en) | 2005-11-16 |
| US20040167109A1 (en) | 2004-08-26 |
| CA2516790A1 (en) | 2004-09-02 |
| PL378209A1 (pl) | 2006-03-20 |
| CN1750829A (zh) | 2006-03-22 |
| JP2006518383A (ja) | 2006-08-10 |
| UY28203A1 (es) | 2004-08-31 |
| WO2004073608A2 (en) | 2004-09-02 |
| TW200507858A (en) | 2005-03-01 |
| AU2004212900A1 (en) | 2004-09-02 |
| CN100431544C (zh) | 2008-11-12 |
| ZA200505990B (en) | 2006-12-27 |
| KR20050102653A (ko) | 2005-10-26 |
| US20060074061A1 (en) | 2006-04-06 |
| BRPI0407742A (pt) | 2006-02-14 |
| MXPA05008396A (es) | 2006-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006015259A3 (en) | Compounds and compositions as modulators of steroid hormone nuclear receptors | |
| BRPI0510094A (pt) | uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos | |
| CA2711696C (en) | Therapeutic compositions for treatment of ocular inflammatory disorders | |
| EA200601648A1 (ru) | Глюкозамин и общие пролекарства глюкозамин/противовоспалительный агент, композиции и способы | |
| WO2004080413A3 (en) | Uses and formulations for transdermal or transmucosal application of active agents | |
| MXPA05012784A (es) | Lipidos oxidados y usos de los mismos en el tratamiento de enfermedades y desordenes inflamatorios. | |
| MX2019010757A (es) | Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor. | |
| MXPA06014470A (es) | Formulaciones oftalmicas que incluyen antagonistas de alfa 1 selectivas. | |
| BRPI0518228A (pt) | inibidores de cinesina mitótica e métodos de uso destes | |
| TW200637614A (en) | Bendamustine pharmaceutical compositions | |
| CY1112790T1 (el) | Χρηση μαγιας σεληνιου στην αντιμετωπιση της νοσου αλτσχαιμερ | |
| WO2005091853A3 (en) | Methods and compositions for treating il-13 related pathologies | |
| WO2008060362A3 (en) | Methods and compositions for the treatment of skin diseases and disorders | |
| WO2007092065A3 (en) | Compounds and compositions as lxr modulators | |
| AR043252A1 (es) | Formulaciones de glucocorticoesteroides para tratar angiogenia ocular patologica | |
| CL2008000495A1 (es) | Compuestos derivados de tetrahidro-pirazolo[4,3-c]piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alergias, inflamacion, dolor, cancer, entreotras. | |
| AR040130A1 (es) | Esteres de etonogestrel, su uso como anticopceptivo y para el tratamiento de desordenes ginecologicos | |
| MXPA05008561A (es) | Uso de esteroides para tratar personas que sufren de trastornos oculares. | |
| ATE391493T1 (de) | Suspension von loteprednol-etabonat und tobramycin für die topische ophthalmische anwendung | |
| WO2005077122A3 (en) | Compounds and compositions as lxr modulators | |
| WO2007067519A3 (en) | The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions | |
| TW200801031A (en) | Steroid nitrooxyderivatives | |
| AR030345A1 (es) | Metodo de tratamiento de desordenes relacionados con angiogenesis | |
| MXPA05012696A (es) | Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica. | |
| WO2005077124A3 (en) | Compounds and compositions as lxr modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |